InfraReDx has announced new data showing its LipiScan coronary imaging system can rapidly and accurately detect extensive lipid core plaques (LCPs) linked to an increased risk of heart attack during or following percutaneous coronary intervention (PCI).
The US FDA LipiScan system incorporates intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy to help cardiologists identify and characterise LCPs.
The prospective multicentre observational study showed that, in patients with coronary artery disease, PCI of lesions with a large lipid core is associated with a 50% risk of heart attack during or post-procedure compared to only a 4.2% risk for lesions without a large lipid core.
The primary endpoint of the study was the rate of peri-procedural heart attack in the groups with and without a large lipid core plaque (LCP) in the treatment zone as assessed by NIRS and expressed as maxLCBI4mm.
Lead author of the study James Goldstein said the study, utilising InfraReDx's first-generation LipiScan system with NIR spectroscopy, permitted immediate identification of large lipid core plaques known to complicate stenting and suspected to cause most heart attacks.
''By identifying and quantifying these dangerous plaques that are prone to embolisation, the LipiScan system holds the potential to improve patient outcomes and prevent complications in cardiac procedures," Goldstein said.
Results of the study were consistent with prior findings with other intracoronary imaging methods, and found that LipiScan's system identified a much higher relative risk and requires no offline analysis or expert interpretation.